UNSPSC 51162335: Aspirin/promethazine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162335 Aspirin/promethazine/pseudoephedrine is a Commodity code that captures state and local procurement of pharmaceutical products and related medical supplies, though recent solicitations show considerable scope variation. State and local government entities buying under this code include county health departments and multistate cooperative purchasing alliances. Seminole County, Florida has solicited naloxone and drug deactivation systems for community health support through an IFB process, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, has issued an RFP for generic multi-source pharmaceuticals and over-the-counter products to be distributed across participating state and local government facilities including Oregon. Both solicitations require vendors to meet FDA compliance, cGMP certification where applicable, and Drug Supply Chain Security Act requirements, with fixed-fee or tiered pricing models and contractual relationships through authorized wholesalers.

Recent activity centers in Florida and Minnesota, with the MMCAP vehicle extending coverage across multiple states including Oregon. Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) seeks 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the procurement is potentially FEMA-funded and carries a two-year initial term with a one-year renewal option. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) establishes multiple awards for distribution through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with contract effectiveness of July 1, 2026 and two-year terms for new responders. Both solicitations emphasize insurance requirements, E-Verify compliance, and performance accountability, with MMCAP weighting price competitiveness at 75 percent of evaluation criteria.